[{"type": "title", "data": "SUS Buprenorphine Naloxone (Suboxone)  Induction"}, {"type": "category", "data": "Admit/Transfer/Discharge"}, {"type": "note", "data": "Consider consult with site specific addiction service or provincial addiction Rapid Access to Consultative Expertise (RACE) line prior to initiating powerplan "}, {"type": "note", "data": "Alert patients' community pharmacy of hospitalization and consider discontinuation of community opioid prescription if ordering buprenorphine-naloxone in hospital "}, {"type": "category", "data": "Patient Care"}, {"type": "order", "data": "Clinical Opiate Withdrawal Scale (COWS)", "value": "checked"}, {"type": "sentence", "data": "T;N, As per protocol, q2hr while awake until buprenorphine/naloxone is started ad then every shift and PRN thereafter"}, {"type": "order", "data": "Notify Provider", "value": "checked"}, {"type": "sentence", "data": "T;N, Notify provider when COWS score greater than 12"}, {"type": "category", "data": "Medications"}, {"type": "order", "data": "naloxone", "value": "checked"}, {"type": "sentence", "data": "0.1 mg, IV Push, Injection, q2min, PRN, Opiate reversal, 180 day(s)"}, {"type": "sentence", "data": "0.4 mg, IV Push, Injection, q2min, PRN, Opiate reversal, 180 day(s)"}, {"type": "order", "data": "naloxone", "value": "checked"}, {"type": "sentence", "data": "0.1 mg, IM, Injection, q2min, PRN, Opiate reversal, 180 day(s)"}, {"type": "sentence", "data": "0.4 mg, IM, Injection, q2min, PRN, Opiate reversal, 180 day(s)"}, {"type": "note", "data": "Provider MUST verify COWS is greater than 12 prior to first dose. Choose either buprenorphine-naloxone 24 Hour Induction OR buprenorphine-naloxone 3 Day Induction "}, {"type": "note", "data": "24 Hour Induction "}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "1 tabs, SL, SL tab, Once, 24 hr"}, {"type": "sentence", "data": "2 tabs, SL, SL tab, Once, 24 hr"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "1 tabs, SL, SL tab, q1hr, PRN, Symptoms of Withdrawal"}, {"type": "sentence", "data": "2 tabs, SL, SL tab, q1hr, PRN, Symptoms of Withdrawal"}, {"type": "note", "data": "Provider MUST complete buprenorphine-naloxone maintenance order for ongoing therapy after first 24 hours"}, {"type": "note", "data": "3 Day Induction "}, {"type": "note", "data": "Day 1 of induction is complete when a total dose of 12 mg is administered OR if withdrawal symptoms adequately relieved 1 to 3 hours after receiving 8mg or more total dose"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "1 tabs, SL, SL tab, Once, T;N, 24 hr"}, {"type": "sentence", "data": "2 tabs, SL, SL tab, Once, T;N, 24 hr"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "1 tabs, SL, SL tab, q2hr, PRN, T;N, 24 hr"}, {"type": "order", "data": "Notify Provider", "value": ""}, {"type": "sentence", "data": "T;N, Notify provider immediately if COWS score increases or patient reports worsening withdrawal at any time. Hold buprenorphine-naloxone and notify provider immediately if Pasero Opioid-Induced Sedation Scale (POSS) is 3 or greater"}, {"type": "note", "data": "Day 2 of induction is complete if withdrawal symptoms adequately relieved 1 to 3 hours after receiving 8 to 16 mg total dose "}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "2 tabs, SL, SL tab, Once, T+1;0800"}, {"type": "sentence", "data": "4 tabs, SL, SL tab, Once, T+1;0800, 24 hr"}, {"type": "sentence", "data": "6 tabs, SL, SL tab, Once, T+1;0800, 24 hr"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "1 tabs, SL, SL tab, q2hr, PRN, T+1;N, 24 hr"}, {"type": "note", "data": "Day 3 of induction is complete if withdrawl symptoms adequately relieed 1 to 3 hours after receiving 8 to 24 mg total dose"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "2 tabs, SL, SL tab, Once, T+2;0800"}, {"type": "sentence", "data": "6 tabs, SL, SL tab, Once, T+2;0800"}, {"type": "sentence", "data": "8 tabs, SL, SL tab, Once, T+2;0800"}, {"type": "order", "data": "buprenorphine-naloxone 2 mg-0.5 mg sublingual tablet", "value": ""}, {"type": "sentence", "data": "1 tabs, SL, SL tab, q1hr, PRN, T+2;0800"}, {"type": "category", "data": "Laboratory"}, {"type": "order", "data": "Notify Provider", "value": "checked"}, {"type": "sentence", "data": "T;N, Notify provider before induction if HCG positive or positive urine drug screen"}, {"type": "category", "data": "Consults/Referrals"}, {"type": "order", "data": "Consult to Social Worker (SW)", "value": ""}, {"type": "sentence", "data": "T;N, Opioid withdrawal management"}, {"type": "order", "data": "Consult to Indigenous Care Coordinator", "value": ""}, {"type": "sentence", "data": "T;N, Opioid withdrawal management"}]
